SHAREHOLDERS' EQUITY (Tables)

12 Months Ended

Dec. 31, 2022

Equity [Abstract]

Schedule of Shareholders' Equity

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)	2022		2021		2020
Beginning balance	$	(4,562)	$	(4,386)	$	(4,818)
AOCI before reclasses – net of taxes of $127, $(91) and $(25)	(1,355)		(104)		(255)
Reclasses from AOCI – net of taxes of $—, $87 and $—(a)	—		(71)		691
AOCI	(1,355)		(174)		435
Less AOCI attributable to noncontrolling interests	(2)		2		2
Currency translation adjustments AOCI	$	(5,915)	$	(4,562)	$	(4,386)
Beginning balance	$	3,646	$	(5,395)	$	(7,024)
AOCI before reclasses – net of taxes of $597, $1,643 and $(283)	2,117		6,225		(1,256)
Reclasses from AOCI – net of taxes of $216, $793 and $805(a)	772		2,819		2,888
AOCI	2,889		9,044		1,632
Less AOCI attributable to noncontrolling interests	3		3		4
Benefit plans AOCI	$	6,531	$	3,646	$	(5,395)
Beginning balance	$	2,498	$	32	$	109
AOCI before reclasses – net of taxes of $(1,141), $615 and $21(b)	(4,461)		2,422		(39)
Reclasses from AOCI – net of taxes of $(20), $23 and $(25)(a)	36		44		(39)
AOCI	(4,425)		2,466		(78)
Investment securities and cash flow hedges AOCI	$	(1,927)	$	2,498	$	32
AOCI at December 31	$	(1,311)	$	1,582	$	(9,749)
Dividends declared per common share	$	0.32	$	0.32	$	0.32

(a)The total reclassification from AOCI included $836 million, including currency translation of $688 million, net of taxes, in 2020,

related to the sale of our BioPharma business within our HealthCare segment.

(b)Included adjustments of $2,674 million, $3,535 million and $(1,979) million for the years ended December 31, 2022, 2021 and 2020, respectively, related to insurance liabilities and annuity benefits in our run-off insurance operations to reflect the effects that would have been recognized had the related unrealized investment security gains been realized. See Note 12 for further information.